Drug intelligence / Profile preview

RVB-003

Development stage: Preclinical
Lead developer: ResVita Bio
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

RVB-003 is a genetically engineered protein therapeutic developed by ResVita Bio for the treatment of Netherton syndrome, a rare and life-threatening genetic skin disorder. The drug utilizes a novel continuous protein therapy platform that employs genetically engineered probiotic bacteria applied topically to the skin. These bacteria temporarily colonize the skin and continuously release therapeutic proteins—specifically LEKTI (a serine protease inhibitor)—to restore the integrity of the skin barrier by inhibiting uncontrolled protease activity caused by SPINK5 gene mutations. This approach aims to provide sustained delivery of therapy directly at the site of disease, potentially offering improved safety and efficacy over traditional treatments. RVB-003 has received orphan drug designation and rare pediatric disease designation from the FDA for Netherton syndrome[1][2][3][4][5][7].

Targets

KLK5 (Kallikrein-related peptidase 5)KLK7

Beyond the preview

Go deeper on RVB-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVB-003.

Explore the full profile